https://bio.nikkeibp.co.jp/atcl/news/p1/22/08/29/09868/

The company plans to start clinical trials in 2023 for allogeneic soft bone cell sheets for knee osteoarthritis.

CellSeed develops regenerative medical products based on a technology invented by Professor Mitsuo Okano of Tokyo Women’s Medical University that enables cells to be cultured in sheet form. While selling cell culture equipment, the company is also developing regenerative medical products such as esophageal epithelial cell sheets (to prevent stenosis after endoscopic esophageal cancer surgery) and cartilage cell sheets (for knee osteoarthritis).

The allogeneic chondrocyte cell sheet is provided by the National Center for Child Health and Development and stems from cartilage tissue collected from patients with polydactyly.